One of the areas where pregnancy after 35 differs most visibly from pregnancy at younger ages is in the landscape of genetic testing options. For women who conceive at 35 or older, healthcare providers typically offer a broader range of screening and diagnostic tests than they might for younger patients — not because complications are inevitable, but because the statistical probability of certain chromosomal variations increases with maternal age, and information can help individuals make informed decisions about their care.
Navigating these options — with their different purposes, levels of certainty, and implications — can feel overwhelming. This article provides an overview of the most commonly discussed genetic testing options during pregnancy after 35, what research and medical guidelines say about them, and how to approach the conversation with your OB/GYN or maternal-fetal medicine specialist.
Why Genetic Testing Is More Commonly Offered After 35
The primary reason genetic testing is discussed more proactively after 35 relates to chromosomal changes in eggs. As women age, eggs become more susceptible to errors during cell division — a process called aneuploidy — that can result in chromosomal abnormalities in the embryo or fetus. The most well-known is trisomy 21, which leads to Down syndrome, but other trisomies (such as trisomy 18 and trisomy 13) also increase in frequency with maternal age.
According to the American College of Obstetricians and Gynecologists (ACOG), the probability of a chromosomal abnormality at the time of amniocentesis at age 35 is approximately 1 in 200, rising to around 1 in 65 by age 40. ACOG now recommends that all pregnant women — regardless of age — be offered information about genetic screening and diagnostic testing, though the choice of whether to pursue testing is deeply personal.
Screening Tests vs. Diagnostic Tests
Understanding the distinction between screening and diagnostic tests is central to making informed choices:
- Screening tests assess statistical risk — they indicate whether a pregnancy has a higher or lower probability of a chromosomal condition, but they cannot confirm or rule out a diagnosis. A positive screen result means elevated risk, not a confirmed condition; a negative screen result means lower risk, not guaranteed absence.
- Diagnostic tests examine chromosomal material directly and can provide a definitive answer about whether a specific chromosomal condition is present. They carry a small risk of pregnancy loss associated with the procedure.
Many women choose to begin with screening tests and then discuss whether diagnostic testing makes sense based on results and personal preferences. Others prefer the certainty of diagnostic testing from the outset. Both paths are valid, and the right approach depends on individual values, circumstances, and what information would be most useful for decision-making.
Common Screening Options
Cell-Free DNA (cfDNA) / NIPT
Non-invasive prenatal testing (NIPT), also called cell-free DNA (cfDNA) testing, analyzes small fragments of fetal DNA circulating in the mother’s blood. It can be done from around 10 weeks of pregnancy and screens for common trisomies (21, 18, and 13), as well as sex chromosome conditions and, in some versions, certain other chromosomal differences.
NIPT has high sensitivity and specificity for the conditions it tests — particularly trisomy 21 — and is generally considered one of the most accurate screening options currently available. However, it remains a screening test; positive results are typically followed up with diagnostic testing for confirmation. NIPT may be somewhat less reliable in certain situations, such as very early pregnancy or multiple pregnancies.
First Trimester Combined Screening
This approach combines a nuchal translucency (NT) ultrasound measurement with blood tests measuring pregnancy-associated plasma protein-A (PAPP-A) and human chorionic gonadotropin (hCG). It is typically done between 11 and 14 weeks. The combined approach has a detection rate for trisomy 21 of approximately 80–90%, with a false-positive rate around 5%.
Second Trimester Quad Screen
The quad screen (alpha-fetoprotein, hCG, estriol, and inhibin A) is a blood test done in the second trimester, typically between 15 and 20 weeks. It screens for trisomy 21, trisomy 18, and neural tube defects. It can be done alone or as part of integrated screening combining first and second trimester results.
Diagnostic Testing Options
Chorionic Villus Sampling (CVS)
CVS involves taking a small sample of placental tissue, which shares the same genetic material as the fetus. It can be performed between 10 and 13 weeks of pregnancy. CVS can diagnose chromosomal conditions with high accuracy and provides a result relatively early in pregnancy. The procedure-related risk of pregnancy loss is estimated at approximately 0.5–1%, though this varies by provider and setting.
Amniocentesis
Amniocentesis involves sampling a small amount of amniotic fluid, which contains fetal cells. It is typically performed between 15 and 20 weeks. Like CVS, it provides a definitive chromosomal diagnosis. The procedure-related pregnancy loss risk is similarly estimated at approximately 0.1–0.3%, with variation by provider experience and center.
For women considering diagnostic testing, discussing the specific risk estimates and provider experience at their care center is an important part of making an informed decision. Prenatal care after 35 ideally involves open conversations about these options without pressure in either direction.
Making a Decision That Fits Your Values
There is no universally “right” answer about whether to pursue genetic testing, which kind to pursue, or what to do with the results. These decisions are deeply personal and may be influenced by values around information, decision-making, pregnancy management, and a range of other factors. Healthcare providers can explain the options, but the decision belongs to the individual and their partner if applicable.
Some women find that having information — even difficult information — helps them feel more prepared. Others feel that screening introduces anxiety without changing what they would do. Genetic counselors can be an especially valuable resource; they specialize in explaining options, interpreting results, and supporting individuals through the decision-making process. Asking your provider for a referral to a genetic counselor is a reasonable step regardless of which path you’re considering. You can also explore emotional support during pregnancy after 35 as part of navigating these decisions.
Frequently Asked Questions
Is genetic testing required during pregnancy after 35?
No — genetic testing is offered, not required. ACOG recommends that all pregnant women be offered information about available tests, but the choice of whether to pursue testing is always the individual’s. Your provider should support your decision in either direction.
What happens if a screening test comes back positive?
A positive screening result means the pregnancy is at elevated risk for a particular condition compared to average — it is not a diagnosis. Most women who receive a positive screen do not have a baby with the condition screened for. A positive screen is typically followed by consultation and discussion of diagnostic testing options to determine whether the condition is actually present.
What is a genetic counselor and should I see one?
Genetic counselors are healthcare professionals trained in medical genetics and counseling. They can explain testing options in detail, help interpret results, and provide support for decision-making. Seeing a genetic counselor is often recommended when navigating genetic testing options, particularly for complex situations or after an abnormal result.
Does a chromosomal condition detected prenatally predict the severity of its effects?
Chromosomal conditions exist on a spectrum of severity that cannot always be precisely predicted prenatally. Genetic counselors and maternal-fetal medicine specialists can provide information about the range of outcomes associated with specific conditions, which many people find helpful for decision-making.
Key Takeaways
- Pregnancy after 35 is associated with a higher statistical probability of certain chromosomal conditions, which is why genetic testing options are more proactively discussed.
- Screening tests assess risk probability; diagnostic tests provide definitive chromosomal information with a small procedural risk.
- NIPT is among the most sensitive screening options for common trisomies, but positive results require diagnostic confirmation.
- Genetic counselors are a valuable resource for navigating options, interpreting results, and supporting decision-making.
- The choice of whether to pursue genetic testing — and which kind — is deeply personal and should be made without external pressure.
Medical Disclaimer
This content is for informational purposes only and does not constitute medical advice. Individual health situations vary significantly. Always consult a qualified healthcare provider before making decisions related to your health, fertility, or pregnancy.
About the Author
Emily Carter is a women’s health writer focused on fertility, pregnancy after 35, and sleep changes in midlife. She writes research-informed, non-alarmist content to help women navigate reproductive and hormonal transitions with clarity and confidence.